EMA
approval
· 2024-02-08
EMA Authorised: Ambirix (hepatitis A virus (inactivated);hepatitis B surface antigen) — GlaxoSmithKline Biologicals S.A.
Summary
Ambirix has been authorised for immunization against hepatitis A and hepatitis B infections.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Hepatitis B;Hepatitis A;Immunization. MAH: GlaxoSmithKline Biologicals S.A.. Decision date: 01/02/2024